Filing Flows › LifeStance Health Group (LFST) › Q2 2026 › vs Q2 2025
LifeStance Health Group (LFST) Q2 2026 vs Q2 2025 (year over year)
LifeStance Health Group's revenue rose $90.0M (+26%) from $345M in Q2 2025 to $435M in Q2 2026. Operating margin 7.0% against -0.9% (+7.9 pts).
LifeStance Health Group, Q2 2026: revenue $435M (+26% year over year), operating margin 7.0%, net earnings $23.6M, operating cash flow $99.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.0% | -0.9% | +7.9 pts |
| Net margin | 5.4% | -1.1% | +6.5 pts |
| Free cash flow margin | 20.2% | 16.4% | +3.8 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $435M | $345M | $90.0M | +26% |
| Operating profit | $30.7M | −$3.0M | $33.6M | — |
| Costs & expenses | $405M | $348M | $56.4M | +16% |
| Pre-tax earnings | $27.5M | −$5.9M | $33.4M | — |
| Other expense, net | $3.2M | $3.0M | $204K | +7% |
| SG&A | $108M | $97.4M | $10.8M | +11% |
| Other operating costs | $297M | $251M | $45.7M | +18% |
| Net earnings | $23.6M | −$3.8M | $27.4M | — |
| Income tax | $3.8M | −$2.2M | $6.0M | — |
| Depreciation & amortization | $11.3M | $10.6M | $670K | +6% |
| Share-based compensation | $19.7M | $21.1M | −$1.4M | -6% |
| Working capital & other | $45.2M | $36.4M | $8.8M | +24% |
| Operating cash flow | $99.9M | $64.4M | $35.5M | +55% |
| Free cash flow (OCF − capex) | $87.9M | $56.6M | $31.3M | +55% |
| Capital expenditures | $12.0M | $7.8M | $4.2M | +55% |
Questions
How much did LifeStance Health Group's revenue grow year over year in Q2 2026?
LifeStance Health Group's revenue rose $90.0M (+26%) from $345M in Q2 2025 to $435M in Q2 2026. Operating margin 7.0% against -0.9% (+7.9 pts).